Description: E-Qure Corp. owns intellectual property (IP) of technology of wound healing device. The IP assets, including the wound healing device, are designed for wound treatment incorporating Bioelectrical Signal Therapy (BST Device). The BST Device implements electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The BST Device, using electrodes affixed around the opposing sides of the wound, emits an electrical field around the wound and therefore mimics the electrochemical physiology principle and induces local cell regeneration. The BST Device is used to treat severe stage II, as well as stage III and IV wounds, including pressure ulcers, diabetic ulcers and venous ulcers. The BST Device is a device for adjunctive therapy in wound healing. The BST Device is able to automatically adjust the electric pulse amplitude based on a patient's impedance reading.
Home Page: www.e-qure.com
20 West 64th Street
New York,
NY
10023
United States
Phone:
972 891 6733 3
Officers
| Name | Title |
|---|---|
| Mr. Ohad Goren | CEO & Director |
| Mr. Gal Peleg | Chief Financial Officer |
| Mr. Itsik Ben Yesha | CTO & Director |
| Mr. Itai Weisberg | Chief Marketing Consultant |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 319.069 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1 |